Return to flip book view
A new chapter beginstoday in the India–UKeconomic partnership! Thesigning of theComprehensive Economicand Trade Agreement(CETA) reflects our sharedcommitment to enhancingtrade, driving inclusivegrowth and creatingopportunities for farmers,women, youth, MSMEs,and professionals.www.pharmexcil.comSupported by JULY 2025Hon’ble Mr Narendra ModiPrime Minister of The Republic ofIndia Hon’ble Rt. Sir Keir StarmerPrime Minister of TheUnited KingdomA landmark dealwith India meansjobs, investment andgrowth here in theUK. It createsthousands of Britishjobs, unlocks newopportunities forbusinesses and putsmoney in the pocketsof working people Message English हिंदी Scan Here for Flip Book
Ministry of Commerce and IndustryGovernment of IndiaSUPPORTED BY: ORGANIZED BY:All Round ExportPerformanceAPI/Bulk DrugsFormulationsExcipientsBio-PharmaVeterinaryWomanEntrepreneur AwardSME Export AwardExportStartup AwardRegional AwardsContract Research &ManufacturingSurgicalsMerchant Exporter+++++++++++++SpecialAwardsCelebrating India’sPharma ChampionsJoin us at IPHEX 2025and celebrate India’s best! 4th Sept 2025 | 10.00 am OnwardsBharat Mandapam, New DelhiLast date tosubmitapplication- 8thAugust 2025Join us as we honour the trailblazers,innovators and exporters drivingIndia’s global pharma leadership.Recognizing excellence across:Enquiries:stats@pharmexcil.com& awards@pharmexcil.com Scan here to submitthe applicationAwards forOutstanding ExportPerformance for thefinancial year 2023-244-6 SEPTEMBER NEW DELHI 2025 Bharat Mandapam, New DelhiPharmaceuticals ExportPromotion Council of India(S et u p b y Min is tr y o f com me rce & I ndu st ry, g ov ern me nt of I ndi a)
NEW MEMBERSNepalForeword04Export/Import Performance 06Pharmexcil Activities 08INDIA-UK Free Trade Agreement20Regulatory Updates25Registration Procedures27Pharmexcil in News 28NotificationsDGFT, CDSCO,DoP29Members Achievements 3233AVAIL ONLINE SERVICES 34MAI,COO,RCMCRepresentation 35Norway, France, BrazilPharma News31
India's pharmaceutical sector continues to solidify its pivotal role in the global healthcarelandscape, With pharmaceutical exports soaring to $7.57 billion in the April-June quarter of FY26,the industry has achieved a robust 5.21% growth compared to the same period last year. In a landmark moment for global trade, the India–UK Comprehensive Economic and TradeAgreement (CETA) was signed by Hon’ble Prime Minister Mr Narendra Modi and Hon’ble UK PrimeMinister Sir Keir Starmer. This historic pact unlocks zero-duty access for 99% of Indian exports,including pharmaceuticals, significantly enhancing India's competitiveness in the UK market. Theagreement also streamlines professional mobility and digital services, further empowering India’spharma sector to expand its global footprint. Heartfelt congratulations to both Prime Ministers forthis visionary achievement that not only strengthens bilateral ties but also accelerates inclusivegrowth across industries. Their leadership has paved the way for a resilient and innovation-drivenfuture.While the digitization of services is a welcome step toward modernization, the current ONDLSrollout has introduced delays in the export process. As the system undergoes refinement,stakeholders remain optimistic that these short-term challenges will lead to long-term efficiencyand transparency in pharmaceutical logistics. Collaborative feedback will be key to ensuring asmooth transformation.During the month, the NDLS team and Pharmexcil discussed LeMP, a platform to streamlinepharmaceutical logistics by enhancing transparency, integrating compliance, competitive pricing,value-added services, route optimization, digital documentation, real-time tracking, and feedback.Key sessions covered Una’s Bulk Drug Park investment, India–US Rules of Origin impactingexporters, and India–Russia talks on regulatory barriers and procurement access. Monica Goud’sconsultation highlighted pharmaceutical localization trends in Africa, urging adaptive strategies,while India–Peru and India–Chile negotiations focused on market expansion and overcoming non-tariff barriers. The SBER Bank–Russian Delegation meeting explored financial cooperation,including digital ruble integration and alternative payment systems, aligning with India–Russiaefforts to strengthen economic resilience within BRICS. Future webinars will engage exporters toadvance these initiatives.ForewordChairmanNamit JoshiForewordPharmexcil Digest Page 4
Director GeneralRaja BhanuThe success of our ongoing initiatives reinforces Pharmexcil's commitment to empowering India’spharmaceutical exporters with data-driven insights, strategic engagements, and global outreach.We extend our sincere appreciation to member companies for their positive feedback and to thePharmexcil team for curating this publication with dedication and precision.We gratefully acknowledge the support of Additional Secretary Mr.Nitin Kumar Yadav, IAS,Department of Commerce, whose leadership has been pivotal in steering regulatory clarity andconvening high-level reviews, such as the 5th Monthly Meeting on pharma and medical devicestrade held on 11 July 2025. These dialogues continue to strengthen compliance levels and elevateIndia’s pharma exports.Pharmexcil’s operational engagements, including MAI application processing, Certificate of Origin(Non-Preferential) issuance, and RCMC allocation to new companies, reflect the Council’s efficiencyand responsiveness.We take pride in the momentum building towards iPHEX 2025, scheduled from 4–6 September.With Hon’ble Commerce & Industries Minister Mr. Piyush Goyal’s continued guidance, ourproposed B2B web platform will serve as a digital gateway for global buyers, empowering exportersthrough product visibility, seamless interaction, and e-ordering capabilities. We look forward to welcoming all participants as India showcases its strength in affordable andinnovative healthcare solutions on the world stage.Pharmexcil Digest Page 5
2066 2068 21232262 224420842428 2468230526152468 2475NAFTA39.30%LAC6.26%EUROPE18.16%CIS3.34%NEA 2.94%WANA 4.98%AFRICA12.08%S.ASIA 3.73%OCEANIA2.13%ASEAN5.80%APR MAY JUNEFY 22 FY 23 FY 24 FY 25050010001500200025003000Value in $ Mn206620682123226220842244242823052468248624752615India's Export Performance ofPharmaceutical Products June 25Pharmaceutical exports during the periodJune‘25 were USD 7577.64 million andbetween 2024-25 and 2025-26 there hasbeen a growth of 5.20%. When compared to exports in May 2024-25 (USD 2468.84Mn) during last FY,exports in the month of May 2025-26(USD 2475.70 Mn) have expanded by5.95%. Category wise, exports in pharma duringJune 2025-26, has been led by DrugFormulations and Biologicals which wasworth USD 5744.11 million. NAFTA, regions which grew significantlywere OCEANIA (20.24%), LAC (7.07%),Other regions which grew moderatelywere AFRICA (1.78%), EUROPE (1.40%),NEA (1.49%) and SOUTH ASIA (1.48%). OVERVIEW75.9%15.9%3.6%2.1%Drug formulations & BiologicalsBulk Drugs, Drug IntermediatesVaccinesSurgicalsAyush and Herbals Products Growth5.95%Exports2615.67 $Mn708.60 $MnImports Growth0.03 %Pharmexcil Digest Page 6
India's Import Performance ofPharmaceutical Products June 25India’s imports during the period of June2025-26 have increased by 4.21%. Importsduring this period have been valued at785.99 USD million. It has also been observed that importsbetween June 2024-25 (USD 708.01mn)and June 2025-26 (USD 708.69 Mn)· India’s major categories of pharmaproducts imported during June 2025-26were Bulk Drugs and Drug Intermediateswhich comprised 46.20% of India’s totalpharma imports. The value of imports in this category wasUSD 327.44 million. Imports in thiscategory decreased by 12.19%. NEA(-16.62%), LAC (-36.32%), NAFTA (-2.45%),WANA (-38.08%), OCEANIA (25.12%) andAFRICA (30.96%) were the regions whereimports have contracted. Marked in Red. OVERVIEW708695 712577702666762708684787748708NAFTA12.70%LAC0.64%EUROPE36.38%CIS0.25%NEA40.47%WANA 0.42%AFRICA0.27%S.ASIA 0.52%OCEANIA0.63%ASEAN 7.72%APR MAY JUNEFY 22 FY 23 FY 24 FY 250200400600800Value in $ Mn70869571257770266668476270874878770846.1%31%15.9%4.1%2.8%Drug formulations & BiologicalsBulk Drugs, Drug IntermediatesVaccinesSurgicalsAyush and Herbals ProductsPharmexcil Digest Page 7
PHARMEXCIL ACTIVITIES03.July.2025:Meeting on NLeMP export Cycle- Pharmexcil with NDLSThe NDLS team discussed cooperation with Pharmexcil on a platform that seeks to unify andenhance transparency among logistics stakeholders—exporters, importers, service providers, andregulators. By centralizing services and information, NLeMP will streamline operations currentlyhindered by fragmentation and opaque practices. Key features include integrated compliancemanagement, competitive pricing through bidding models, booking of value-added services likewarehousing and insurance, route optimization, digital document exchange, real-time tracking, anda feedback mechanism to improve service quality. Future webinars will be planned for memberexporters.The meeting was attended by Mr Rollins John, Director, Pharmexcil.08.July.2025:Meeting with Mr.Nico Schiettekatte, Counselor for Health,Welfare & Sport, Embassy of NetherlandsMr.Nico Schiettekatte, Counselor for Health,Welfare & Sport, Embassy of the Kingdom of theNetherlands in India, Ms.Ravleen Pal, DeputyHead of Economic Section, Sector Lead -Lifesciences & Health, Mr Harsh Indrarun, Tradeand Investment Commissioner, Mr.Rambabu,Head , Hyderabad Netherlands BusinessSupport Office visited Pharmexcil HyderabadOffice. Mr.Raja Bhanu, Director General,Pharmexcil welcomed the officials fromNetherland and invited Dutch companies totake part in iPHEX 2025 scheduled from 04-06.Sep.2025 at Bharat Mandapam, New Delhi.It was requested to invite Dutch companiesand Procurement Authority Officials for theB2B meetings and Mr.Nico updated that theOfficials related to Hospitals Services,Wholesalers, Healthcare, Insurance havebeen invited to participate in iPHEX 2025. Discussed the possibilities of Dutch Pavilionand Mr.Kamal shared the costing involved forthe Pavilion.Mr.Murali, Director joined the meetingdiscussed on the shortages by API and FDFproduct wise and sought information fromMr.Nico for assessing the potential to supplyand effective match making.Pharmexcil Digest Pharmexcil Digest Page8
09.July.2025:Meeting chaired by Secretary, DoP to engage Centre for WTOStudies on Pharma and Medical Devices Sector Studies in Centre for WTOStudies, DelhiMr.Raja Bhanu, Director General Pharmexciland Mr. Murali Krishna had an online meetingwith MAH International Corporation tounderstand their services.S. Carmela S. Carmela, Attorney at Law, LLM(UK), Director Export Accounts Receivable &Dispute Resolution introduced MAHInternational Corporation's services toPharmexcil and offered to support membercompanies with international paymentchallenges.Mr.Namit Joshi, Chairman, Pharmexcil participated in the meeting chaired by the Secretary,Department of Pharmaceuticals to engage Centre for WTO Studies on Pharma and MedicalDevices Sector Studies. Deliberated on HSN classification, product data and tariff barriers andCentre for WTO Studies to share the ToRs/action plan for the same.10.July.2025: Meeting with M.A.HInternational Corporation, SwitzerlandMAH handle cases across all exportindustries, treating each as an outstandingpayment and applying our proven five-stepamicable recovery process. With ourexperience in recovering payments from 124countries, and our strong presence acrossEurope, North America, South America, theMiddle East, and Africa,MAH InternationalCorporation promised to provide specificinformation about their experience withpharmaceutical exporters and expressedwillingness to conduct a webinar.Pharmexcil Digest Page9
11.July.2025: Meeting withMs.Bruna on Brazil Meets India:Health Regulatory EcosystemThe meeting was joined by Mr.Namit Joshi,Chairman, Mr.Raja Bhanu, Director General,Mr.Murali, Director, Pharmexcil physically andMs.Bruna from Brazil joined virtually. Continuingon the deliberations had with Brazil Embassy,New Delhi, discussed the possibilities ofmounting a high level delegation comprising ofANVISA officials, Brazilian pharma companies foriPHEX 2025. It is also discussed to have a G2Gwith CDSCO and ANVISA and industry interactionwith ANVISA during the three day event11.July.2025: Stakeholder consultationswith the industry on trade negotiationswith Peru and Chile chaired by Mr. VimalAnand, IAS, Joint Secretary, DoC, inRoom No 22, Vanjya Bhawan, DelhiThe stakeholder consultation chaired by Mr.Vimal Anand, IAS, Joint Secretary, DoC, andMs.Monica Gaur,Director examined the risingtrend of pharmaceutical localization in countrieslike Peru and Chile, driven by supply chainvulnerabilities and economic self-reliance,presenting both opportunities and challengesfor Indian exporters. Joined by Mr. Murali,Director, Pharmexcil and highlighted the needfor a coordinated strategy to monitor trends,gather intelligence via Indian missions andfinancial institutions, and proposed streamliningproduct registration in Peru by initiallyaccepting Zone-II stability data, followed byZone-IV to accelerate market access.Discussions on trade negotiations with Peru andChile emphasized expanding market access forpharmaceuticals, automobiles, electronics, andagriculture, while securing critical minerals likecopper and lithium and addressing non-tariffbarriers. Successful consultations underscoredtransparent engagement and collaborativeproblem-solving, with action points assigned toindustry bodies and a call for data-driven, cross-sectoral coordination to strengthen India’strade position in Latin America. Pharmexcil Digest Page 10
Mr. Nitin Kumar Yadav, IAS, Additional Secretary,DoC chaired the 5 Review meeting on Pharmaand Medical Devices trade performance. Themeeting was joined by Mr. Namit Joshi, Chairman,Mr. Bhavin Mehta, Vice Chairman, Pharmexcil,Mr. Raja Bhanu, Director General Dr. VishalRajgharia, Mr. Bharat Desai , Members of CoA. thKey Discussions: 1.Localization Trends:- concerns discussedrelated to the impact of localization on exports,emphasizing the need for a comprehensivestrategy to monitor localization trends.- Thestrategy will be a part of the study beingconducted by CWTOS engaged by DoP. Atentative deadline of 1 month to be considered,post which the feasibility of the study to beevaluated. Pharmexcil acknowledged theimportance of tracking localization investmentsby Indian companies abroad and suggested usingmission offices for better visibility. 2. Regulatory Issues:- Concerns were raisedregarding the transition to an online system forissuing Certificates of Pharmaceutical Product(COPP) and the associated problems with C-DACportal.The need for a clear turnaround time (TAT) forboth applicants and issuing authorities wasemphasized to avoid delays in exports. A meetingto be scheduled with CDSCO to address theseissues and pre-existing industry’s issues. 11.July.2025: 5th Monthly Meeting chaired by Mr. Nitin Kumar Yadav, IAS, AdditionalSecretary, Department of Commerce to review the trade performance of Pharma andMedical Devices in Conference Room No. 13, Vanijya Bhawan, DelhiCDSCO urged exporters to bring their exportrelated issues on an individual case to-case basis.3. Import Trends: Import surge in 30021290:Others of Antisera and Other Blood Fractions Asignificant increase in imports of human albuminwas noted, and thus Pharmexcil was enquiredabout the reasons behind this surge. Thecommodity is of essential category and mostlyimported for government procurement and not acause of concern. 4.Country-Specific Trade Issues:- Concernsregarding trade with Pakistan were raised, witha request for clarification on whether exports toPakistan have been halted. It was clarified thatat present DGFT Notification, regardingrestriction on imports with Pakistan is in placeand the notification is self-explanatory in itself.There is no other DGFT order with respect toexports to Pakistan. The need for a unifiedapproach to address trade restrictions imposedby other countries, particularly in Africa, wasemphasized.5. Written Confirmation for APIs:- Delays in therenewal of written confirmations for APIs inEurope were discussed, with industryrepresentatives highlighting the lengthy processand lack of clarity. The importance of aligningthe CDSCO and industry expectations tostreamline the renewal process was highlightedPharmexcil Digest Page 11
11. July.2025: Interaction on Investment in BulkDrug Park, Una, HimachalpradeshThe interactive session was attended by around45 member exporters with interests inmanufacturing and investing in Bulk Drugs andKey Starting Materials (KSMs). Mr. Prajapatiand his team delivered a presentationhighlighting the benefits of the Bulk Drug Parkin Una and addressed participants’ queriesduring the session. The meeting was attendedby Mr. Rollins John, Director, Pharmexcil.The meeting was chaired by Mr. Gayatri Nair,Economic Adviser, Department ofPharmaceuticals (DoP). Discussions focused onProduct Specific Rules (PSRs) under the UnitedStates–Mexico–Canada Agreement (USMCA),assimilar Rules of Origin (ROO) may be proposedby the U.S. in its upcoming trade agreement withIndia. Pharmexcil, along with IDMA and IPA,shared concerns that for certain HSN codes, thevalue addition thresholds set under ROO areexcessively high and could discourage Indianmanufacturers already operating in the U.S.market. Stakeholders have been requested tosubmit detailed comments, and a follow-upmeeting has been scheduled. The meeting wasattended by Mr. Rollins John, Director,Pharmexcil.Mr. Rakesh Kumar Prajapati, IAS, Director ofIndustries, Government of Himachal Pradesh,chaired the meeting, accompanied by Mr. Tilak RajSharma, Additional CEO-cum-Coordinator. 15.July.2025:Discussion with Department ofPharma (DoP) on Product Specific Rules (PSRs)for India US Bilateral Trade Agreement15.July.2025:Sber Bank-Russian DelegationSBER Bank with the support of Pharmexcil organised business meetings at Hyderabad joined by fiveRussian Pharmaceutical companies from Russia side and representatives from Aurobindo Pharma ,MSN Labs, Biocon, Cohance, Biological E, Shilpa Medicare etc had meetings with the Russiancompanies.Mr. Batalov Artem, Head of Corporate & Financial Institutional Development, Mr. Prem Sharma,Director from SBER Bank joined and Mr. Murali Krishna S, Director, Pharmexcil. Discussedopportunities for inviting Russian companies for iPHEX scheduled from 04-06.Sep.2025 at New Delhi.Pharmexcil Digest Page 12
21.July.2025: Meeting with Mr. Adolfo Garcia Estrada, Consul General,Consulate of Mexico, Mumbai.A meeting was held at Pharmexcil’s Mumbai office on 21st July 2025 with Mr. Adolfo GarciaEstrada, Consul General of Mexico, to explore deeper collaboration in the pharmaceuticalsector. Mr. Rollins John, Director and Ms. Dipti , Assistant Director joined the meeting fromPharmexcil.Key discussions included:Webinar Proposal: A webinar with Pharmexcil members is tentatively scheduled for 13thor 14th August 2025 to introduce Mexico’s development strategy and promote investmentopportunities, especially in APIs, formulations, biomedicines, and biosimilars.iPHEX 2025 Participation: Potential involvement of Mexican counterparts or buyers in theiPHEX 2025 exhibition was discussed to foster international partnerships. LAC Delegation: Inclusion of Mexico in Pharmexcil’s planned delegation to the Latin Americaand Caribbean region was considered to expand Indian pharma exports. October Meeting Request: The Consul General requested a meeting in October withPharmexcil’s Director General and key Indian pharma companies to further strategicdiscussions.16.July.2025: 5th Session of India-Russia Sub Working Group on Eliminationof Restriction and Barriers in Trade, Economic & Investment Spheres The meeting was attended by Mr. Rollins John, Director, Pharmexcil. The 5th Session of theIndia-Russia Sub-Working Group on Elimination of Restrictions and Barriers in Trade,Economic, and Investment Spheres was co-chaired by Mr. Mohit Yadav, Joint Secretary,Department of Commerce. Key issues raised included reference pricing the registrationprocess, and limited market access in public procurement. Final comments by the Russianside on these matters are still awaited and are expected by August in the next round ofdiscussions. Pharmexcil Digest Page 13
Pharmexcil Digest 24.July.2025: Meeting with Mr. Steven Connolly, Deputy Consul General ,ConsulateGeneral of Australia, Bangalore. Mr. Steven Connolly, Deputy Consul General ,Consulate General of Australia, Bangalore Ms.Sangeetha Krishnamoorthy, Senior Director - Trade & Investment Australian Trade and InvestmentCommission met Mr. Raja Bhanu,Director General and Team as a courtesy visit. Discussed aboutIndia-Australia Pharma trade matters, potential collaborations in the space of R & D, iPHEX 2025and sought support from Austrade for inviting Pharmaceutical companies from Australia. Joinedby Mr. Prashant K, Joint Director and Mr. Murali, Director, PharmexcilDr.Viranchi Shah, Member CoA, Pharmexcil met Hon’bleUnion Minister Mr.Piyush Goyal, Ministry of Commerce &Industry and invited Hon’ble Minister for iPHEX 2025. Mr.Amit Chawla, Member CoA ,Pharmexcil met Hon’ble UnionMinister Mr.J P Nadda, Ministry of Health & Family Welfare Pharmexcil Digest Page 14
Pharmexcil in association with Embassy of India at Romania organized "India-Romania Pharma BusinessOpportunities" & B2B. H.E. Dr. Manoj Kumar Mohapatra, Ambassador of India to Romania welcomed the guests present fromRomania and India side, thanked them for their participation and presented the perspective of India-Romania trade relations and significance of the Pharmaceuticals as a thrust sector. Shared the strengths ofIndia Pharma industry and its immense contribution to the healthcare expenditure of many countries.Mr. Vlad Matei shared the guidelines of Medicinal Food Supplements in Romania and Mr. Gerald FlintoacaFilip, Consultant in the field of pharma in Romania spoke about the potential for generic medicines.Mr. Raja Bhanu, Director General, Pharmexcil thanked H.E. Dr. Manoj Kumar Mohapatra, Ambassador ofIndia to Romania and presented the potential for India -Romania pharma trade and invited the Romania sideto join iPHEX 2025 scheduled from 04-06.Sep.2025 at Bharat Manadapam,New Delhi. A number of 15 companies from Romania had B2B with 125 companies from India side.Mr.Murali ,DirectorPharmexcil coordinated the B2B Session.Mr.Mahesh Chand, Second Secretary (Commerce) proposed the Vote of Thanks. 30.July.2025: India – Romania Pharmaceutical OpportunitiesWebinar & B2B SessionPharmexcil Digest Page 15
The Curtain Raiser Ceremony ofthe 11th edition of iPHEXThe Curtain Raiser Ceremony of the 11th edition of iPHEX 2025 was graced by eminent dignitaries,including Mr. Amit Agrawal, IAS, Secretary, Department of Pharmaceuticals, Ministry ofChemicals and Fertilizers; Mr. Nitin Kumar Yadav, IAS, Additional Secretary (EP-Pharma), Ministryof Commerce & Industry; Dr. V. Kalaiselvan, Secretary-cum-Scientific Director, IPC; Mr. R.Chandershekar, Joint Drugs Controller, CDSCO; Mr. Pankaj Chadha, Chairman, EEPC INDIA; Mr.Namit Joshi, Chairman, PHARMEXCIL; Mr. Bhavin M. Mehta, Chairman – iPHEX 2025 & ViceChairman, PHARMEXCIL; and Mr. Raja Bhanu, Director General, PHARMEXCIL. Mr. Namit Joshi spoke about the evolution of India’spharmaceutical industry and the critical role of iPHEX indriving global engagement. He underlined itscontribution in creating B2B linkages, showcasinginnovation, and strengthening regulatory cooperationto boost India’s pharmaceutical exportsPharmexcil Digest Page 16
Mr. Amit Agrawal shared India’s aspirations to lead inpharmaceutical innovation, particularly in emergingfields like personalized medicine and biotechnology.He highlighted various government initiativessupporting R&D and emphasized embracing digitalhealth technologies to reinforce global leadershipMr. Bhavin M. Mehta emphasized India’s evolvingrole as a global healthcare leader, underlining theimportance of innovation and collaboration in thepharmaceutical sector. He highlighted iPHEX as aplatform for fostering meaningful partnerships andoutlined the strategic vision to position India as afrontrunner in medicine production and innovationMr. Raja Bhanu detailed iPHEX 2025’s rolein highlighting India’s strengths in APIs,biosimilars, and vaccines, while focusing onregulatory convergence and global traderelationships. He emphasized iPHEX as apivotal platform for building long-termpartnerships and ensuring India’s continuedleadership in global healthcare.Mr. Nitin Kumar Yadav spoke on India’s standing as apharmaceutical powerhouse and the significance ofiPHEX in strengthening international partnerships andglobal trade. He stressed India’s shift towardspharmaceutical innovation while maintaining high globalstandards.Pharmexcil Digest Page 17
Mr. R. Chandershekar reiterated India’s role asthe “Pharmacy of the World,” focusing on thecountry’s contribution to supplying essentialmedicines and vaccines worldwide. He alsostressed the need to uphold stringent regulatorystandards, promote innovation inbiopharmaceuticals, and enhance internationalcollaborations for sustainable healthcare.www.reallygreatsite.comMr. Pankaj Chadha shared the launch ofLabNext Expo and Med Expo—held under thebanner of Bharat Health were well-received.Mr. Chadha expressed his satisfaction with theoutcomes and conveyed optimism for deepercollaboration and future partnerships in thepharmaceutical sector.Mr. Amit Agrawal, IAS, Secretary,Department of Pharmaceuticalslaunched the July Edition ofPharmexcil Digest, a specialedition on India-UK Free TradeAgreement Page 18Pharmexcil Digest
iPHEX 2025 Brochure launched by theDignitaries at the Curtain Raiser Mr.Nitin Kumar Yadav,IAS,Additional Secretary,MoC launched EXIM PharmaDashboard developed by Pharmexcil during the Curtain Raiser ProgrammePharmexcil Digest Page 19
Pharmexcil Digest A landmark moment signing our trade deal withIndia at Chequers today. This deal is a major winfor Britain, delivering quality jobs, puttingmoney in the pockets of hardworking Brits, andhelping with the cost of living. It is great newsfor workers, businesses and consumersINDIA- UK CETAThe “India-UK Free Trade Agreement” (FTA)marks amilestone in economic cooperation, particularly inthe field of pharmaceuticals, stronger supply chains,& improved access to affordable medicines & infostering Foreign Direct Investment (FDI),encouraging collaborationsIt was signed by Hon’ble Union Minister Mr. Piyush Goyal, Ministry of Commerce andIndustry The Republic of India and , Hon’ble UK Business and Trade Secretary Mr. JonathanReynolds “Benchmark Deal… trade will double by2030”Union commerce minister argues tradepact with UK will not just make India amajor exporter to Britain and benefitsIndian companies, it will also increase infarming & fishing communitiesHon’ble Union Minister Mr. Piyush Goyal, Ministry ofCommerce and Industry The Republic of India Hon’ble UK Business and Trade Secretary Mr. Jonathan Reynolds, United KingdomPharmexcil Digest Page 20
Pharmexcil Digest Page 21
UK Market Report Market Overview Pharmexcil Digest Page 22Trade Data: Exports to top 10 Countries inEurope (USD in Million)Generic Drug ForecastGeneric drug sales reached an estimated USD 7.2bn in 2024, which we expect to rise by 2.1% toUSD 7.8bn in 2025. By 2029, the generic drug market is forecast to reach a value of USD 9.4bn,equating to a five-year compound annual growth rate (CAGR) of 5.4%.OTC Drug ForecastIn 2024, the OTC market is estimated to have reached USD 11.1bn, and we expect it to grow byto USD 12.2bn in 2025. By 2029, OTC medicines sales are expected to reach USD 15.3bn,posting a five- year compound annual growth rate (CAGR) of 6.5%.In 2024, UK pharmaceutical market wasestimated at USD 35.1bn and expectspending to grow by 9.0% to USD38.3bn in 2025. By 2029, forecast ofpharmaceutical spending to reach a valueof USD 46.4bn, reaching a five-yearcompound annual growth rate (CAGR) of5.7%.Patented Drugs ForecastIt is estimated that the patented drugmarket is valued at USD 16.8 bn in 2024,which is expecting to rise by USD18.3 bn in 2025. By 2029, forecast high-value originator drug sales toreach USD 21.8 bn, equating to a five-yearcompound annual growth rate (CAGR) of5.3%.U K19.6%FRANCE15.3%GERMANY13.9%NETHERLAND13%BELGIUM11.3%MALTA6.2%SPAIN5.5%POLAND5.1%ITALY5.1%TURKEY5.1%EXPORTS TO UK (USD IN MILLION) IMPORTS FROM UK (USD INMILLION)25-Apr 26-AprDrugs formulations & BiologicalsBulk Drugs & Drug IntermediatesSurgicalsAyush & HerbalsVaccines050100150200Value in USD Mn178.32189.7319.6117.2225-Apr 26-AprDrugs formulations & BiologicalsBulk Drugs & Drug IntermediatesSurgicalsAyush & HerbalsVaccines0510152025Value in USD Mn16.8720.486.3613.262.532.76
Pharmexcil Digest Page 23Exports Growth Potential/Strategy:Leverage Growth in Generics and Biosimilars Focus on Generics: With 81% of drugs prescribed in the UK being generics , India shouldemphasize cost- effective, high-quality generics to support the NHS’s cost-savingmeasures.Biosimilars: Target biosimilar opportunities, especially for drugs like Adalimumab, whichsaved the NHS GBP1.2 billion over three years .Enhance Contract Manufacturing and R& DContract Manufacturing for NHS: Offer India’s cost-efficient manufacturing capabilities tomeet the NHS’s demands for affordable medicines and essential drugs.New Drug Development: Align with UK initiatives like the Innovative Medicines Fund andVPAG to promote Indian-made innovative drugs for rare diseases.Antimicrobial Drugs: Explore collaboration under the Antimicrobial Products SubscriptionModel to develop and export antibiotics listed on the WHO priority list .United States of America20.1%Germany17.1%Italy13.1%Ireland10.7%Switzerland9.4%Belgium8.2%Singapore6.9%France5.5%Spain5%India4%TOP 10 FORMULATIONS IMPORTING PARTNERS-FY 24India- UK CETAIndia side wishPharmaceutical annexinclusion in the next round ofnegotiation to enhancemarket access, fast trackregulatory processes, andfoster bilateral trade.
Pharmexcil Digest Largest Export Destination in Europe:The United Kingdom is India’s most significant pharmaceuticalexport destination within Europe, highlighting the deep trade tiesbetween the two countries in the healthcare sector.Strong Presence in the Generics Market:Indian pharmaceutical companies have carved out a dominantposition in the UK, particularly in the segment of genericmedicines, which are central to the country’s public healthcaredelivery.Substantial Share in NHS Supply Chain:Approximately 80% of all prescriptions dispensed by the UK’sNational Health Service (NHS) are for generic medicines,underscoring their critical role in making healthcare moreaffordable and accessible.India’s Contribution to NHS Generics:Around one-third of these generic medicines prescribed by theNHS are manufactured in and exported from India, showcasingIndia’s reliability and competitiveness as a global supplier.Regulatory Compliance and Quality Standards:Indian pharmaceutical firms comply with stringent UK and EUregulatory norms, including MHRA and EU GMP certifications,which has helped them build credibility and sustain long-termpartnerships.Page 24
020305Product Registration ApplicationDDA reviews submitted documents.Conducts site inspections fir non- SRA- approved Companies Issues Product Registration Certificate (Schedule 4E).0405PROCEDURESREGISTRATION Company RegistrationSubmit an application in Schedule 4C format.Provide manufacturing license, Certificate ofPharmaceutical Product (COPP), and productdossier.Conduct stability testing and bioequivalencestudies (if applicable).01Renewal & VariationsRenewal required every two years.Submit updated GMP certificate, stability data,and ADR reports.05Submit an application for company registration.Provide a Site Master File and GMP compliance documents.Obtain approval from the Department of Drug Administration(DDA).Checklist for Company Registration (Link)Evaluation & ApprovalImport Recommendation LetterProvide importer authorization, pricing details, andmarket authorization.DDA issues Import Recommendation Letter(Schedule 7).020304Pharmexcil Digest Pharmexcil Digest Page 25
GMP GUIDELINESGMP Inspection Process01Submit an application with Site Master File, facilitylayout, and compliance documents.National GMP Code 207202Preliminary ReviewDDA reviews submitted documents for completeness.Schedules on-site inspection.03On-Site Inspection (Inspectors Access)Optimized facility design, streamlined production with qualityassurance, trained personnel maintaining hygiene, and secure storagefor effective distribution.03Compliance AssessmentVerify adherence to WHO-GMP standards.Identify deficiencies and request Corrective and Preventive Action(CAPA).04Final Review & CertificationIf compliance is satisfactory, DDA issues GMP Certification.GMP Certification NoticeOngoing Monitoring & RecertificationGMP-certified manufacturers undergo periodic audits.Recertification required every two years.For complete Registration Guidance0605Pharmexcil Digest Pharmexcil Digest Page 26
Pharmexcil Digest July 3, 2025| Errors in medical record systems when ordering ADHDmedicationsAn e-prescription error affects short-dose entries for methylphenidatehydrochloride (10–60 mg) across SFM and FM modules since June 29, 2025.Automatic dosage suggestions are unavailable; doctors should use free text fordosing until the FEST update on July 11. Pharmacies may receive prescriptionswith manual dosage inputs; renewals remain unaffected. Patients prescribedADHD medications will experience no disruption in treatment.(Link)Regulatory Updates1.July 07, 2025| Tips to improve the quality of your dossierand get a CEP fasterTo streamline your CEP application, submit a complete, well-structured dossieraligned with EDQM guidance and ICH/EMA quality standards. Key areas includenitrosamine risk assessment (EMA Q&A), starting material definition (ICH Q11),and control of mutagenic impurities (ICH M7). Refer to EDQM’s dossier contentdocument for compliance expectations and use e-learning modules 5–9 forpractical preparation. High-quality, consistent documentation reduces delays andimproves the chance of a smooth evaluation process.(Link)July 07, 2025| Anvisa invites the pharmaceutical sector toparticipate in an international public consultation on GoodManufacturing PracticesAnvisa invites Brazilian Pharma stakeholders to participate in an internationalpublic consultation on updated EU–PIC/S GMP guidelines. Key documentsinclude Chapter 4 (Documentation), Annex 11 (Computerized Systems), andthe newly added Annex 22 (Artificial Intelligence). Contributions are open untilOctober 7 via sector entities or the EU Survey platform. Industry involvementis vital to ensure local needs are reflected in global GMP harmonization.(Link)Pharmexcil Digest Page 27
Pharmexcil Digest Pharmexcil Digest Page 28 PHARMEXCIL IN NEWSPharmexcil opensdialogue with US onstrengthening tradefacilitation, market accessfor IndianpharmaproductsPharmexcil invitesCroatia and Austriapharma delegation toexplore iPHEX -2025to enhance bilateraltradePharmexcil hostsmedia delegationfrom Eastern andSouthern Africa tostrengthen trade tiesPharmexcil urges exportersto act swiftly as Botswanamandates pre-shipmentinspection effective fromJuly 1, 2025Duty relief toboost pharmacompanies' accessto UK drug stores.
P H A R M A N E W S01020304Pharmexcil opens dialogue with USon strengthening trade facilitation,market access for Indian pharmaproducts.(Dt:02.07.25)India and Myanmar in talks to fast-track approval for pharma productsin Myanmar.(Dt:04.07.25)Govt Panel proposes Braille Cards,Voice enabled QR codes onMedicine packs to aid visuallyimpaired.(Dt:06.07.25)0506Pharmexcil invites Croatia andAustria pharma delegation toexplore iPHEX -2025 to enhancebilateral trade. (Dt:07.07.25)FOPE president asks MSMEs toimplement revised Schedule M asgovt unlikely to extend deadline..(Dt:08.07.25)Pharmexcil Digest Pharmexcil Digest Page 29India and Uzbekistan eye strategicpharma collaboration tostrengthen bilateral trade.(Dt:08.07.25)07Pharma companies may soonget GST relief shot on free drugsamples. (Dt:09.07.25)08091011121314Domestic pharma industry willhave to pass on high tariff impactto US consumers.(Dt:10.07.25)Pharmexcil urges exporters to actswiftly as Botswana mandates pre-shipment inspection effective fromJuly 1, 2025.(Dt:10.07.25)India’s Pharma War Zone: HowDelhi’s Bulk Drug Push Is RattlingChina.(Dt:10.07.25)Small pharma cos struggle withrevised Schedule M complianceamid resource & expertise gaps:Harish Jain.(Dt:11.07.25)CDSCO switches over to onlinesubmission of clinical trialapplications for CGTP.(Dt:12.07.25)Pharmexcil urges memberexporters to respond to Mauritiusmedicine requirement.(Dt:12.07.25)Delay Implementation of ONDLS– Only COPP submission Model:Pharmexcil request CDSCO,Health Ministry.(Dt: 12.07.25)
151617181920Pharmexcil Digest Pharmexcil Digest Page 302124252627282930BDMAI to launch e-marketingportal for APIs, intermediates &pellets to offer products to national& intl markets.(Dt:14.07.25)Pharmexcil flags export disruptionrisk from CoPP mandate; seeksurgent policy review.(Dt:15.07.25)DGFT seeks industry feedback ondraft internal complianceprogramme for export of dual-useor SCOMET items.(Dt:17.07.25)Centre extends deadline for onlinesubmission of WHO-GMP COPPapplications till August 15.(Dt:17.07.25)Experts analyse OBBBA’s impacton Indian pharma industry.(Dt:18.07.25)CDSCO issues SEC guidancedocument elaboratingapplication, recommendationprocesses. (Dt:21.07.25)FPME’s “Export Pe Charcha”highlights merchant exporters’ rolein making drugs globally accessible.(Dt:21.07.25)22FPME concerned over DCGI directivenot allowing export of drugs labelledas ‘meant for sale in India’CIPMMA calls on Uniongovernment to exempt pharmamarketers from quality liability.(Dt:24.07.25).Centre eyeing import curbs onPharma raw materials to boostlocal production: Report.(Dt:24.07.25).Govt. provides update on schemesimplemented in the pharma sector.(Dt:24.07.25)NPPA directs stakeholders toalign MRP of non-scheduledformulations as per DPCOprovisions.(Dt:25.07.25)UK FTA to boostcompetitiveness of Indiangenerics in UK market: Tradeexperts. (Dt:26.07.25).31Pharmexcil announcesproduct enquiry foritraconazole supply to Dubaibased buyer(Dt:25.07.25)23Government plans minimum importprice for key Pharma inputs.(Dt:23.07.25).Telangana IDMA warns ofclosure of small & micro units ifrevised Schedule M deadline isnot extended. (Dt:28.07.25).Indian cuts API imports, disbursesRs.1,008 Cr under PLI schemes,Parliament told. (Dt:26.07.25).32Duty relief to boostpharma companies' accessto UK drug stores.(Dt:25.07.25)
NOTIFICATIONSTimeline extended till 21.07.2025 -Invitation of applications for eligibleproducts under the ProductionLinked Incentive Scheme for BulkDrugs.(Dt: 04.07.25) DGFT,DoP,CDSCOPharmexcil Digest Pharmexcil Digest Page 31Fixation of new Standard InputOutput Norms (SIONs) at SION (A-3687, A-3688 and A-3689 under‘Chemical and Allied Product’(Product Code ‘A’).(Dt: 08.07.25) Extension of timeline for grant ofWHO GMP COPP through ONDLSportal.(Dt:15.07.2025)Revised Export NOC Guidancedocument for Manufacture ofUnapproved / Approved New Drugsalong with Annexures.(Dt: 17.07.25)Clarification regarding applicabilityof Para 2.12 of the Foreign TradePolicy.(Dt: (Dt:22.07.25)Amendment in ANF-2N for issuanceof export authorization of PharmaGrade Sugar.(Dt:22.07.25)Issues related to safety ofRanitidine drug due to presence ofNDMA impurity. (Dt:24.07.25)Correlation of TechnicalCharacteristics, Quality andSpecification of the Inputs with theExport Product under the DFIAScheme.(Dt:24.07.25)
M E M B E R SA C H I E V E M E N T S02.03.01.Lupin arm Dabhasa facility gets GMP certificationfrom TGA Australia - 19.07.2025Venus Remedies secures WHO GDP endorsement forpharma logistics - 21.07.2025Indoco receives Certificate of EU GMP Compliancefrom European Health Authorities for its sterile drugproduct manufacturing facility, Goa Plant II 24 072025Pharmexcil Digest Pharmexcil Digest Page 32“"We warmly invite memberexporters to showcase theircompany’s achievements on thePharmexcil website every month. Weare delighted to feature theseaccomplishments in our newsletter,further amplifying their visibility andimpact within the industry."”
BULK DRUGS & DRUGBULK DRUGS & DRUGINTERMEDIATESINTERMEDIATESDRUGS FORMULATIONS &DRUGS FORMULATIONS &BIOLOGICALSBIOLOGICALSGRANDE ETOILE PHARMACEUTICALS LTDUNIVERSE CAPSULES BIOTECH PVT LTDNOVAMED LABORATORIES PVT LTDDCM SHRIRAM INDUSTRIES LTDPANDITATA RESEARCH TECHNOLOGYANDROST BIOTECH PVT LTDBANNARI AMMAN SUGARS LTDMEDICAL NEXUS INFRASTRUCTURES PVT LTDINNO PHARMACEUTICAL COMPANYACTIVIN CHEMICALS AND PHARMACEUTICALSPVT LTDPAROSHA CHEMICALS PVT LTDHENI CHEMICAL INDUSTRIESDERIVATE LABS PVT LTDALKIMIA PHARMA-CHEM PVT LTDWATERLILY ENTERPRISEVENU HEALTH CAREUTTAM SUGAR MILLS LTDKRITTIK PHARMA PVT LTDBIOLUXE PHARMA LLPVEROSYNTH CHEMICALS LTDASAI VISHWA SPECIALITY CHEMICALS PVT LTDEVEREST DISTRIBUTIONS PVT LTDAPISYN HEALTHCARE PVT LTDSSV PHARMA PVT LTDARAGEN LIFE SCIENCES LTD25253434New MembersSHREE NARMADA KHAND UDYOGSAHAKARI MANDALI LTDPROSPERITY 6 PHARMACEUTICSMARUSH OVERSEAS PVT LTDJADUNEX-MEDMOLECULES INNOVATIONPVT LTDKASSS ENTERPRISESASHISH MEDICAMENTS LLPSHREEN INTERNATIONALPAKHI AND PAKHI PHARMANITROALKANES SPECIALIST PVT LTDSOLBRILLANT PHARMACEUTICALS PVT LTDSDS BUSINESS HUBBAFAKYH PHARMACEUTICALS PVT LTDALPINE HEALTHCARE HOSPITAL LLPSHANIA HEALTHCARE PVT LTDIREX PHARMACYAMERICAN MIDDLE EASTERN MEDICALSOLUTIONS PVT LTDALIBEX LIFESCIENCESPHERONIC LIFESCIENCE PVT LTDDOCUSES HEALTHCARE INDIA PVT LTDLEOWIN HEALTHCARE LLPRAPROSS PHARMACEUTICALS PVT LTDZAZEN HEALTHCARE PVT LTDXENON PHARMACEUTICALSUNIREVA HEALTHCARE LLPORCA LABS PVT LTDGLOBAL MATRIXMEDITELL PHARMACEUTICALS PVT LTDEN EM LIFE SCIENCESROHAN PHARMA PVT LTDSHREE SWASTIK FOOD PRODUCTSANANTHAPUR MEDICAL HUBRR OVERSEASSHUBH LIFE CAREBRITAIN HEALTHCAREPharmexcil Digest Pharmexcil Digest Page 33NUTRACEUTICAL PRODUCTSNUTRACEUTICAL PRODUCTS0303GUARDIAN HEALTHCARE SERVICES PVTLTDUNNATI MARKETINGPHARMACO HEALTHCARESURGICALSSURGICALS0303OSPS BLISS PHARMA PVT LTDREGENXGEN BIOSOLUTIONS PVT LTDACMA GLOBAL TRADE0101WAYMADE INDIA PVT LTDPHARMACEUTICAL SERVICESPHARMACEUTICAL SERVICES
ONLINE SERVICESMarket Access Initiative:Product Registration Plant inspectionPatent filingBA/BE StudiesClinical TrialsMAI Applications Recommended -July MonthRecommended to DoC-19Returned-12Certificate of Origin COO-(Non Preferential): Members can obtain COO onlineTime for Issuance (same day)No.of COO's issued : 172 (Month of July) RCMC MEMBERSHIP Registration/RenewalRCMC's issued month of June: Click here to Apply for NewMembership/RenewalExport Performance Certificate /GST : ( Offline)Members can obtain certificateTime for Issuance (24 hrs)No.of Certificate 's issued : 26 (Month of July)The Pharmexcil Helpdesk WhatsAppservice, launched on July 11, 2024,enhancing communication formembers by providing dedicatedcontact points:Pharmexcil Help DeskMembers can interact via chat only (nocalls) during working hours (10 AM -6:30) PM, weekdays) for real-timeassistance, clarifications, and update +91 8977024106 – Handles queriesrelated to the Market Access Initiative(MAI). +91 8977025106 – Covers Certificate ofOrigin (CoO), RCMC, Events & RegulatoryGuidance.tes on Government Schemes and policies.Appointments of AdvisorsDGFT Matters Customs and GST Advisor-dgftmatters@pharmexcil.comadvisor-gstcustoms@pharmexcil.comPharmexcil has appointedAdvisors for addressing thematters relating to DGFT,Customs & GST. Member companies facingissues/requiring advise onDGFT, Customs & GST can nowavail the services by sendingrequest to the following emailidsPharmexcil Digest Pharmexcil Digest Page 34
The exporters sought clarification on export/DGFT restrictions on pharmaceutical exports to Pakistan, as noofficial circular has been found, and clarity is needed to avoid financial losses and ensure compliance.In light of this, guidance is sought on the following points:Whether DGFT has issued any specific notification prohibiting or restricting the export of pharmaceuticalproducts, including Active Pharmaceutical Ingredients (APIs) and finished formulations, to Pakistan.If such restrictions exist, kindly provide the relevant notification number, date, and comprehensivedetails of the items covered under such a prohibition or restriction.Whether any exemptions or special procedures are available for exporters who have already receivedadvance payments and confirmed orders prior to the imposition of such restrictions, to avoid severefinancial losses and contractual breaches.We emphasize the importance of this clarification to avoid financial losses for our member exporters,prevent contractual breaches with international buyers, and minimize disruption of the pharmaceuticalsupply chain. Your intervention and prompt clarification on this matter will enable our memberexporters to take appropriate action in full compliance with Government policy.Representation: Seeking clarification on Export restrictions of Drugs andPharmaceuticals to Pakistan PHARMEXCIL Representation to DGFT & CDSC0Pharmexcil Digest Pharmexcil Digest Page 35The Initiative undertaken by CDSCO West Zone in collaboration with FDA Maharashtra and IDMA, whichincluded a training session on 23rd June 2025. Technical experts from CDAC demonstrated the portal’sfunctionality to over 260 in-person attendees and 2380 online participants. During the session, severalstakeholders, including FDA officials and industry representatives, highlighted a number of technical andprocedural challenges. CDAC experts assured attendees that these concerns would be addressed.Manufacturing units highlighted significant operational challenges with the ONDLS system during a recentsession with CDAC, CDSCO, and Maharashtra FDA. Issues ranged from tedious manual entry of old licenses,lack of real-time editing, and limits in adding technical staff, to restrictive contact information policiesrequiring separate mobile numbers and emails for each site or loan license. Additional concerns included roleconflicts created by system requirements, incomplete uploads (such as site plan copies), and the lack offlexibility in updating shelf life and pack size post-approval—affecting business agility. Participants alsopointed out system inefficiencies like repeated document uploads for applications, absence of tracking ortimelines for approvals, and inadequate online payment infrastructure. The lack of integration with theSugam and XLN portals means firms are forced to re-enter massive datasets manually, which is nearlyimpossible within tight retention timelines. Most pressing, this bottleneck jeopardizes WHO COPPcertification and export commitments, calling for urgent system enhancements to avoid regulatory andcommercial setbacks.During the month of May 2025, exports of Drugs & Pharmaceuticals to the ROW market is to the tune of USD1bn contributing to 44.43% share of total India exports of Pharmaceuticals growing at 5%. It is reiterated thatsuch sudden enforcement may jeopardize nearly 45% India’s pharma exports to RoW markets.It would be appropriate to mention the Pharmexcil experience with CDAC in respect to the implementation ofTrack & Trace system by CDAC is not very effective and expensive in nature without any outcomes. In light of this, we respectfully request that the directive to initiate applications for WHO COPP exclusivelythrough the ONDLS portal be deferred until:The system issues identified during the training session are resolvedCDAC implements necessary upgrades and provides robust supportA revised rollout plan is shared to minimize disruptionsWe are confident that with adequate time and consultation, the ONDLS portal can become a reliable tool forcertification management. However, combining its rollout with immediate WHO COPP applicationrequirements could hinder export continuity and cause undue hardship to industry stakeholders.ONDLS SYSTEM BY CDSCO
Dashboard Launch Announcement – 31st July 2025Following our preview in the last edition of the Digest, Pharmexcil is delighted to announcethe official launch of its EXIM Data Dashboard on 31st July 2025.Developed as a strategic intelligence tool for member exporters, this platform offersinteractive access to key export-import performance indicators. From market insights andproduct trends to destination-wise analytics, the dashboard empowers users to makesmarter, data-backed decisions in a dynamic trade environment.Key Highlights: Export Trend Analysis with real-time visuals Country-specific demand snapshots Top exported pharmaceutical products by volume, value & growth Customizable filters for deeper explorationThis milestone aligns with Pharmexcil’s continued commitment to enhancing transparencyand fostering global competitiveness through timely and actionable intelligence.We invite all members to explore this new service and unlock opportunities in globalmarkets. https://pharmexcil.com/export-performance-dashboard
FORTH COMING EVENTS Empowering Global Pharma OutreachBlock your dateswww.pharmexcil.comPharmexcil is pleased to update its members on key industry platforms that promise rich opportunitiesfor global engagement and export growth:iPHEX 2025 – New Delhi (4–6 July)India’s flagship pharmaceutical exhibition offers a dynamic interface between exporters and international buyers,regulatory authorities, and government agencies. Why It Matters:Facilitates direct B2B interactionsShowcases India's export capabilities across therapeutic segmentsEnables market access conversations with high-potential regions CPHI Worldwide – Frankfurt, Germany (28–30 October)As the world’s largest pharma networking event, CPHI brings together innovation, manufacturing excellence, andtrade potential on a truly global stage. Why It Matters:Positions Indian companies before global procurement leadersEncourages regulatory and trade collaborationsDrives diversification and strategic partnershipsWe will be sharing event-specific details, participation opportunities, and strategic support in the next edition ofPharmexcil Digest. These platforms are vital stepping stones in advancing India's pharma presence worldwide.LAC Delegation: Inclusion ofMexico in Pharmexcil’splanned delegation to theLatin America and Caribbeanregion was considered toexpand Indian pharmaexports.